PerkinElmer launches high-volume COVID-19 test workstations

PerkinElmer (NYSE:PKI) announced today that it launched a series of Explorer workstations for increasing COVID-19 testing capabilities.

Waltham, Mass.-based PerkinElmer touts its Explorer workstations as capable of preparing and running up to 10,000 COVID-19 tests per day, enabling laboratories to ramp up their testing for the SARS-CoV-2 virus causing coronavirus and generate quick results.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

PerkinElmer launches dried blood spot COVID-19 serology test

PerkinElmer (NYSE:PKI) announced today that it launched a dry blood spot (DBS) based test for SARS-CoV-2 IgG amid the COVID-19 pandemic.

Using the Waltham, Mass.-based company’s GSP/DELFIA platform that processes up to 5,000 samples per day, the finger-prick sample system allows for decentralized sample collection and high-throughput testing, according to a news release.

The DBS assay runs on the GSP analyzer system, which combines with the universal time-resolved fluorescence (TRF) of the DELFIA platform. The workflow associated with the system includes sample collection, punching, measurement, reagents and software to detect anti-SARS-CoV-2 IgG antibodies.

PerkinElmer said it is marketing the product as a CE-IVD test with plans to apply for FDA emergency use authorization (EUA).

“Dried blood spot samples have been used in large scale population screening programs for decades and can help alleviate the costs and logistical constraints assoc…

Read more
  • 0

MedTech 100 roundup: Industry hits pandemic peak

After five months since medtech stocks peaked before the COVID-19 pandemic rocked the markets, the industry inched back toward that pre-pandemic high.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 88.9 points at the end of last week (July 17). That total represents just a -3.7% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.

Medtech stocks saw a 5.1% increase from the 84.39-point total at the same time a week prior (July 10), highlighting a large improvement after last week saw almost no material change in the index.

Meanwhile, the S&P 500 Index saw a 1.2% bump from July 10 to July 17, and the Dow Jones Index fared even better, posting a 2.3% increase over the same period of time. Both indexes mirrored the medtech industry’s changes as far as increases, but didn’t see as drastic a change.

Medtech’s lowest point du…

Read more
  • 0

PerkinElmer expects strong Q2 results from COVID-19 testing

PerkinElmer (NYSE:PKI) said today that it anticipates sales growth of approximately 12% for the second quarter, fueled by demand for COVID-19 tests and related products.

The Waltham, Mass.-based diagnostic and scientific instrument company said demand for its RT-PCR and serology tests, RNA extraction systems and kits and automated liquid handling instrumentation was particularly robust. COVID-19 related solutions contributed approximately $190 million of revenue in the quarter ended July 5, 2020, the company noted.

Get the full story on our sister site, Drug Discovery & Development.

Read more
  • 0

Report: PerkinElmer under investigation for Medicare fraud

PerkinElmer (NYSE:PKI) is under federal scrutiny for alleged involvement in a scam to bill Medicare for tens of thousands of unnecessary genetic cancer tests, according to a report by Reuters.

The news agency cited three unidentified sources and government documents linking the Waltham, Mass.-based diagnostic and scientific instrument company to the probe. PerkinElmer acknowledged that it has received government subpoenas regarding investigations into third parties and said it is cooperating with authorities, but denied knowledge of wrongdoing.

Get the full story on our sister site, Drug Discovery & Development.

Read more
  • 0